patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_643214 | REC_0015201 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.6 | 67 | female | 1 | 10 | 6.4 | 4 | osimertinib 80 mg daily | 17.5 | true | MSI-H | 2026-03-15T05:36:01.100424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279142 | REC_0015202 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 14 | 62 | male | 1 | 19 | 5.9 | 1 | osimertinib 80 mg daily | 6.1 | true | MSI-H | 2026-03-15T05:36:01.100892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631168 | REC_0015203 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 14 | 7.6 | 54 | female | 0 | 13 | 5.2 | 1 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:36:01.101334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363935 | REC_0015204 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6 | 80 | female | 2 | 49 | 6.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.1 | false | MSS | 2026-03-15T05:36:01.101766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488522 | REC_0015205 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 14.1 | 72 | female | 2 | 15 | 3.9 | 6 | entrectinib 600 mg daily | 4.8 | true | MSS | 2026-03-15T05:36:01.102208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487923 | REC_0015206 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 16 | 12.8 | 79 | male | 1 | 6 | 6.8 | 0 | entrectinib 600 mg daily | 44.9 | false | MSI-H | 2026-03-15T05:36:01.102601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677428 | REC_0015207 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 36 | 11.9 | 66 | male | 0 | 17 | 6.4 | 8 | osimertinib 80 mg daily | 6.9 | false | MSI-H | 2026-03-15T05:36:01.107386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997175 | REC_0015208 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 14.2 | 68 | female | 1 | 10 | 4.8 | 2 | sotorasib 960 mg daily | 18.4 | true | MSS | 2026-03-15T05:36:01.107958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287767 | REC_0015209 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 11.5 | 65 | female | 0 | 19 | 4.3 | 5 | pembrolizumab 200 mg q3w | 11.4 | true | MSS | 2026-03-15T05:36:01.108533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116609 | REC_0015210 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 16.2 | 73 | female | 1 | 15 | 5.4 | 5 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:36:01.108985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455191 | REC_0015211 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 16.2 | 65 | male | 0 | 11 | 6.2 | 4 | alectinib 600 mg BID | 6.1 | true | MSS | 2026-03-15T05:36:01.109580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397492 | REC_0015212 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 14.6 | 78 | female | 2 | 21 | 6.8 | 3 | osimertinib 80 mg daily | 8.3 | true | MSI-H | 2026-03-15T05:36:01.109982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999034 | REC_0015213 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 9.5 | 90 | male | 1 | 12 | 6.2 | 2 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:36:01.110341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385143 | REC_0015214 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 7.5 | 74 | male | 2 | 11 | 5.2 | 6 | osimertinib 80 mg daily | 7 | true | MSS | 2026-03-15T05:36:01.110699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646271 | REC_0015215 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 3.4 | 78 | male | 1 | 18 | 5.3 | 4 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:36:01.111101+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541283 | REC_0015216 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 13.2 | 66 | male | 0 | 9 | 5.9 | 6 | osimertinib 80 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:36:01.111521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409037 | REC_0015217 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 12.5 | 66 | male | 0 | 13 | 6.8 | 4 | pembrolizumab 200 mg q3w | 19.2 | false | MSS | 2026-03-15T05:36:01.111911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254030 | REC_0015218 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 26 | 12.1 | 76 | female | 0 | 21 | 5 | 0 | entrectinib 600 mg daily | 56.9 | true | MSI-H | 2026-03-15T05:36:01.112479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329539 | REC_0015219 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 5.5 | 62 | male | 0 | 37 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.7 | true | MSS | 2026-03-15T05:36:01.112875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172765 | REC_0015220 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 8.5 | 79 | female | 1 | 23 | 5.1 | 6 | osimertinib 80 mg daily | 15.2 | true | MSS | 2026-03-15T05:36:01.113263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992773 | REC_0015221 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9.8 | 61 | male | 0 | 5 | 7.3 | 1 | alectinib 600 mg BID | 11.6 | true | MSS | 2026-03-15T05:36:01.113662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612141 | REC_0015222 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 6 | 73 | female | 2 | 13 | 4 | 5 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:36:01.114058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483207 | REC_0015223 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 9.5 | 66 | female | 0 | 16 | 5.2 | 3 | alectinib 600 mg BID | 22.9 | true | MSS | 2026-03-15T05:36:01.114455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390246 | REC_0015224 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 3.4 | 77 | female | 2 | 56 | 8.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 15 | true | MSS | 2026-03-15T05:36:01.114978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186630 | REC_0015225 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 9.1 | 67 | female | 0 | 6 | 5.1 | 5 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:36:01.115414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256690 | REC_0015226 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 18.4 | 73 | female | 1 | 14 | 4 | 2 | entrectinib 600 mg daily | 21.6 | true | MSS | 2026-03-15T05:36:01.115831+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105894 | REC_0015227 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 13.1 | 69 | female | 1 | 12 | 4.3 | 2 | osimertinib 80 mg daily | 21.3 | false | MSI-H | 2026-03-15T05:36:01.116291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328561 | REC_0015228 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 9.3 | 71 | female | 2 | 17 | 5.9 | 1 | osimertinib 80 mg daily | 18.9 | true | MSS | 2026-03-15T05:36:01.116679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836318 | REC_0015229 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 7 | 73 | female | 2 | 19 | 6.9 | 7 | pembrolizumab 200 mg q3w | 12.6 | true | MSS | 2026-03-15T05:36:01.117048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338773 | REC_0015230 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 8.1 | 63 | female | 1 | 26 | 6.4 | 4 | sotorasib 960 mg daily | 8.2 | false | MSS | 2026-03-15T05:36:01.117445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550987 | REC_0015231 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.1 | 56 | male | 0 | 24 | 7.2 | 7 | alectinib 600 mg BID | 11.5 | false | MSS | 2026-03-15T05:36:01.117842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171320 | REC_0015232 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 24.6 | 61 | male | 0 | 20 | 4.2 | 2 | alectinib 600 mg BID | 21.1 | false | MSS | 2026-03-15T05:36:01.118246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825057 | REC_0015233 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 6.1 | 55 | female | 1 | 29 | 6.1 | 9 | sotorasib 960 mg daily | 14.3 | false | MSS | 2026-03-15T05:36:01.118636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564889 | REC_0015234 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 9.6 | 61 | female | 1 | 9 | 5.5 | 5 | osimertinib 80 mg daily | 5.3 | false | MSS | 2026-03-15T05:36:01.119019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924495 | REC_0015235 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 8.8 | 60 | male | 1 | 19 | 6.4 | 1 | osimertinib 80 mg daily | 24.3 | true | MSS | 2026-03-15T05:36:01.122120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468830 | REC_0015236 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 13.9 | 69 | female | 1 | 16 | 5.6 | 2 | entrectinib 600 mg daily | 18.2 | false | MSS | 2026-03-15T05:36:01.122607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772679 | REC_0015237 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 7.6 | 67 | female | 0 | 17 | 4.6 | 7 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:36:01.123285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633985 | REC_0015238 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 16.6 | 76 | female | 2 | 12 | 5.2 | 1 | sotorasib 960 mg daily | 16.2 | true | MSS | 2026-03-15T05:36:01.123809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647161 | REC_0015239 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.3 | 64 | male | 1 | 42 | 8.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.7 | false | MSS | 2026-03-15T05:36:01.124323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_911171 | REC_0015240 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.5 | 74 | female | 1 | 54 | 7.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 6.8 | false | MSS | 2026-03-15T05:36:01.124766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534377 | REC_0015241 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 12.8 | 60 | female | 1 | 14 | 5.9 | 4 | sotorasib 960 mg daily | 6 | true | MSS | 2026-03-15T05:36:01.125205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460902 | REC_0015242 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 12.8 | 51 | female | 0 | 13 | 5.2 | 1 | sotorasib 960 mg daily | 30.6 | false | MSI-H | 2026-03-15T05:36:01.125615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218544 | REC_0015243 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 6.5 | 65 | male | 0 | 17 | 6.2 | 7 | sotorasib 960 mg daily | 8.1 | true | MSS | 2026-03-15T05:36:01.126045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_630332 | REC_0015244 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 10.6 | 58 | female | 1 | 19 | 6.1 | 2 | entrectinib 600 mg daily | 12.3 | false | MSS | 2026-03-15T05:36:01.126437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186409 | REC_0015245 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.2 | 57 | male | 0 | 17 | 3.1 | 5 | alectinib 600 mg BID | 10.1 | true | MSI-H | 2026-03-15T05:36:01.126833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676050 | REC_0015246 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 6.4 | 69 | female | 0 | 13 | 4.5 | 7 | osimertinib 80 mg daily | 4.3 | false | MSS | 2026-03-15T05:36:01.127254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722732 | REC_0015247 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 7 | 79 | female | 2 | 44 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.9 | true | MSS | 2026-03-15T05:36:01.127632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501367 | REC_0015248 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 15.8 | 65 | female | 0 | 6 | 6.4 | 2 | alectinib 600 mg BID | 21.2 | true | MSI-H | 2026-03-15T05:36:01.128021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882455 | REC_0015249 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 37 | 10.8 | 69 | female | 1 | 0 | 4.7 | 6 | alectinib 600 mg BID | 17.3 | true | MSS | 2026-03-15T05:36:01.128462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834820 | REC_0015250 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 20.5 | 72 | female | 1 | 8 | 5 | 8 | alectinib 600 mg BID | 7.1 | false | MSI-H | 2026-03-15T05:36:01.129078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915155 | REC_0015251 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 8.9 | 53 | female | 0 | 12 | 4.6 | 2 | osimertinib 80 mg daily | 5.7 | true | MSS | 2026-03-15T05:36:01.129501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863629 | REC_0015252 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 16.5 | 77 | male | 3 | 19 | 5.1 | 5 | sotorasib 960 mg daily | 11.7 | true | MSS | 2026-03-15T05:36:01.129909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915201 | REC_0015253 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 11.7 | 71 | female | 1 | 15 | 5.6 | 2 | osimertinib 80 mg daily | 21.2 | true | MSS | 2026-03-15T05:36:01.130292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528783 | REC_0015254 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 7.7 | 54 | female | 0 | 81 | 5.7 | 8 | pembrolizumab 200 mg q3w | 4.3 | false | MSS | 2026-03-15T05:36:01.130650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609607 | REC_0015255 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 12.9 | 67 | female | 1 | 15 | 6.8 | 2 | entrectinib 600 mg daily | 5 | true | MSI-H | 2026-03-15T05:36:01.130999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994654 | REC_0015256 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 11.1 | 61 | female | 0 | 22 | 6.9 | 1 | entrectinib 600 mg daily | 15.1 | true | MSS | 2026-03-15T05:36:01.131333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449718 | REC_0015257 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 33 | 5.4 | 72 | female | 3 | 20 | 6.6 | 3 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:36:01.131684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732502 | REC_0015258 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.8 | 60 | male | 1 | 11 | 6.4 | 5 | entrectinib 600 mg daily | 13.8 | false | MSI-H | 2026-03-15T05:36:01.132150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990821 | REC_0015259 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.3 | 68 | male | 1 | 57 | 4.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:36:01.132586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197821 | REC_0015260 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 16.2 | 67 | female | 1 | 14 | 4.8 | 4 | osimertinib 80 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:36:01.132973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670195 | REC_0015261 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 7 | 73 | female | 2 | 8 | 8 | 1 | alectinib 600 mg BID | 19.2 | false | MSS | 2026-03-15T05:36:01.133337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677609 | REC_0015262 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 8.3 | 70 | female | 1 | 51 | 3.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.5 | false | MSS | 2026-03-15T05:36:01.133695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747968 | REC_0015263 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 22 | 14.1 | 62 | male | 1 | 15 | 4.7 | 0 | osimertinib 80 mg daily | 41.5 | true | MSI-H | 2026-03-15T05:36:01.134316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518616 | REC_0015264 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 8.5 | 57 | male | 1 | 56 | 5.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 14 | true | MSS | 2026-03-15T05:36:01.134742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285025 | REC_0015265 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 7.6 | 77 | male | 1 | 48 | 3.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 5.7 | true | MSS | 2026-03-15T05:36:01.135091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402668 | REC_0015266 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.2 | 60 | male | 0 | 0 | 5.7 | 5 | alectinib 600 mg BID | 7.5 | true | MSI-H | 2026-03-15T05:36:01.135408+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242341 | REC_0015267 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 15.9 | 87 | male | 0 | 12 | 6.1 | 1 | alectinib 600 mg BID | 33.6 | false | MSS | 2026-03-15T05:36:01.138366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539023 | REC_0015268 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 26 | 8.2 | 69 | male | 0 | 14 | 6.4 | 0 | osimertinib 80 mg daily | 27.9 | true | MSS | 2026-03-15T05:36:01.138861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548775 | REC_0015269 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10.9 | 53 | female | 0 | 15 | 4.8 | 4 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:36:01.139314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568159 | REC_0015270 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.4 | 71 | female | 1 | 59 | 6.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.8 | false | MSS | 2026-03-15T05:36:01.139701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243171 | REC_0015271 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 19.3 | 82 | female | 2 | 11 | 7.1 | 1 | entrectinib 600 mg daily | 12.3 | false | MSS | 2026-03-15T05:36:01.140169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297186 | REC_0015272 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 15.1 | 77 | female | 1 | 20 | 4.5 | 1 | entrectinib 600 mg daily | 15 | true | MSS | 2026-03-15T05:36:01.140657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671364 | REC_0015273 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 11.2 | 69 | female | 1 | 14 | 6.1 | 4 | entrectinib 600 mg daily | 12.3 | true | MSS | 2026-03-15T05:36:01.141061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241959 | REC_0015274 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 10 | 66 | female | 1 | 12 | 4 | 4 | entrectinib 600 mg daily | 18.7 | true | MSI-H | 2026-03-15T05:36:01.141416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298954 | REC_0015275 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 14.8 | 50 | female | 0 | 13 | 5.7 | 0 | osimertinib 80 mg daily | 16.9 | true | MSS | 2026-03-15T05:36:01.141788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167267 | REC_0015276 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 11.7 | 69 | female | 1 | 22 | 4.1 | 1 | osimertinib 80 mg daily | 24.3 | true | MSI-H | 2026-03-15T05:36:01.142413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849817 | REC_0015277 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 11.9 | 70 | male | 0 | 4 | 5.4 | 7 | alectinib 600 mg BID | 12.5 | true | MSS | 2026-03-15T05:36:01.142903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181688 | REC_0015278 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 17 | 4 | 70 | male | 3 | 13 | 7.3 | 0 | pembrolizumab 200 mg q3w | 39.5 | false | MSS | 2026-03-15T05:36:01.143300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889889 | REC_0015279 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 17.9 | 83 | female | 1 | 11 | 5.7 | 2 | osimertinib 80 mg daily | 25.8 | true | MSS | 2026-03-15T05:36:01.143692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287332 | REC_0015280 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 12.6 | 77 | female | 2 | 25 | 5 | 5 | osimertinib 80 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:36:01.144237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761662 | REC_0015281 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 9.4 | 67 | female | 0 | 21 | 6.4 | 7 | osimertinib 80 mg daily | 13.1 | false | MSS | 2026-03-15T05:36:01.144781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579403 | REC_0015282 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 15.6 | 73 | female | 1 | 8 | 4.4 | 0 | alectinib 600 mg BID | 47.1 | true | MSS | 2026-03-15T05:36:01.145207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284901 | REC_0015283 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 19.5 | 82 | female | 0 | 18 | 2.7 | 5 | osimertinib 80 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:36:01.145566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744943 | REC_0015284 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 15 | 63 | female | 0 | 19 | 5.2 | 8 | osimertinib 80 mg daily | 5.7 | true | MSI-H | 2026-03-15T05:36:01.145926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246142 | REC_0015285 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12 | 71 | female | 2 | 11 | 4.1 | 5 | osimertinib 80 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:36:01.146318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247123 | REC_0015286 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 8.1 | 71 | male | 1 | 16 | 7.8 | 3 | entrectinib 600 mg daily | 17.4 | true | MSS | 2026-03-15T05:36:01.146718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721433 | REC_0015287 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 12.5 | 66 | female | 1 | 18 | 5.8 | 7 | alectinib 600 mg BID | 8.5 | true | MSS | 2026-03-15T05:36:01.147099+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210807 | REC_0015288 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 6.7 | 75 | male | 1 | 8 | 4.7 | 2 | alectinib 600 mg BID | 17.6 | true | MSS | 2026-03-15T05:36:01.147488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125660 | REC_0015289 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 13.3 | 65 | male | 0 | 25 | 4.6 | 6 | sotorasib 960 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:36:01.148016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880146 | REC_0015290 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 14.5 | 90 | female | 1 | 16 | 6.5 | 2 | sotorasib 960 mg daily | 12.2 | false | MSS | 2026-03-15T05:36:01.148547+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999960 | REC_0015291 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 29 | 7 | 77 | female | 1 | 44 | 4.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 14.5 | false | MSS | 2026-03-15T05:36:01.148928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801166 | REC_0015292 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6 | 79 | female | 3 | 21 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.1 | true | MSS | 2026-03-15T05:36:01.149334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407919 | REC_0015293 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 31 | 14.8 | 66 | female | 1 | 20 | 3.4 | 3 | pembrolizumab 200 mg q3w | 4.8 | true | MSS | 2026-03-15T05:36:01.149771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136897 | REC_0015294 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 8.5 | 68 | male | 0 | 13 | 6 | 5 | alectinib 600 mg BID | 4.9 | false | MSS | 2026-03-15T05:36:01.150157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336111 | REC_0015295 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 14.1 | 68 | male | 1 | 13 | 7.3 | 1 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:36:01.150544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436157 | REC_0015296 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.8 | 69 | male | 1 | 71 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.6 | true | MSS | 2026-03-15T05:36:01.150904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517328 | REC_0015297 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 16.9 | 85 | female | 2 | 17 | 4 | 2 | sotorasib 960 mg daily | 14.9 | false | MSI-H | 2026-03-15T05:36:01.151296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124222 | REC_0015298 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 13.4 | 66 | female | 0 | 15 | 5.7 | 5 | alectinib 600 mg BID | 13.4 | true | MSS | 2026-03-15T05:36:01.151690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148209 | REC_0015299 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.3 | 78 | male | 1 | 12 | 5.5 | 6 | alectinib 600 mg BID | 5.8 | false | MSS | 2026-03-15T05:36:01.152121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556566 | REC_0015300 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 7.1 | 72 | male | 0 | 43 | 5.3 | 2 | pembrolizumab 200 mg q3w | 21 | false | MSS | 2026-03-15T05:36:01.152557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.